Stein Joshua D, Childers David, Gupta Shivani, Talwar Nidhi, Nan Bin, Lee Brian J, Smith Terry J, Douglas Raymond
Department of Ophthalmology and Visual Sciences, School of Medicine, University of Michigan, Ann Arbor.
Department of Biostatistics, School of Public Health, University of Michigan, Ann Arbor.
JAMA Ophthalmol. 2015 Mar;133(3):290-6. doi: 10.1001/jamaophthalmol.2014.5103.
Thyroid-associated ophthalmopathy (TAO) is a common and debilitating manifestation of Graves disease (GD). Presently little is known about factors that may increase the risk of developing TAO among patients with GD.
To identify risk factors associated with the development of TAO among individuals with newly diagnosed GD.
DESIGN, SETTING, AND PARTICIPANTS: In this longitudinal cohort study, all beneficiaries 18 years of age or older with newly diagnosed GD who were continuously enrolled in a large nationwide US managed care network and who visited an eye care professional 1 or more times from 2001 to 2009 were identified. International Classification of Diseases, Ninth Revision, Clinical Modification billing codes were used to identify those who developed manifestations of TAO. Multivariable Cox regression was used to determine the hazard of developing TAO among persons with newly diagnosed GD, with adjustment for sociodemographic factors, systemic medical conditions, thyrotropin levels, and medical and surgical interventions for management of hyperthyroidism.
Manifestations of TAO measured by hazard ratios (HRs) with 95% CIs.
Of 8404 patients with GD who met the inclusion criteria, 740 (8.8%) developed TAO (mean follow-up, 374 days since initial GD diagnosis). After adjustment for potential confounders, surgical thyroidectomy, alone or in combination with medical therapy, was associated with a 74% decreased hazard for TAO (adjusted HR, 0.26 [95% CI, 0.12-0.51]) compared with radioactive iodine therapy alone. Statin use (for ≥60 days in the past year vs <60 days or nonuse) was associated with a 40% decreased hazard (adjusted HR, 0.60 [CI, 0.37-0.93]). No significant association was found for the use of nonstatin cholesterol-lowering medications or cyclooxygenase 2 inhibitors and the development of TAO.
If prospective studies can confirm our finding that a thyroidectomy and statin use are associated with substantially reduced hazards for TAO among patients with GD, preventive measures for this burdensome manifestation of GD may become a reality.
甲状腺相关眼病(TAO)是格雷夫斯病(GD)常见且使人衰弱的一种表现。目前,对于可能增加GD患者发生TAO风险的因素知之甚少。
确定新诊断的GD患者中与TAO发生相关的危险因素。
设计、设置和参与者:在这项纵向队列研究中,确定了所有年龄在18岁及以上、新诊断为GD且持续加入美国一个大型全国性管理式医疗网络,并在2001年至2009年期间至少拜访过一次眼科专业人员的受益者。使用国际疾病分类第九版临床修订本计费代码来确定那些出现TAO表现的患者。多变量Cox回归用于确定新诊断的GD患者发生TAO的风险,并对社会人口统计学因素、全身性疾病、促甲状腺激素水平以及甲亢管理的药物和手术干预进行了调整。
通过风险比(HR)及95%置信区间衡量TAO的表现。
在符合纳入标准的8404例GD患者中,740例(8.8%)发生了TAO(自首次诊断GD起平均随访374天)。在对潜在混杂因素进行调整后,与单独使用放射性碘治疗相比,手术甲状腺切除术单独或与药物治疗联合使用与TAO风险降低74%相关(调整后HR,0.26 [95%置信区间,0.12 - 0.51])。他汀类药物使用(过去一年使用≥60天与<60天或未使用相比)与风险降低40%相关(调整后HR,0.60 [置信区间,0.37 - 0.93])。未发现使用非他汀类降胆固醇药物或环氧化酶2抑制剂与TAO发生之间存在显著关联。
如果前瞻性研究能够证实我们关于甲状腺切除术和他汀类药物使用与GD患者TAO风险大幅降低相关的发现,那么针对GD这种负担性表现的预防措施可能会成为现实。